Citations (63)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Wolfgang H. Jost, Ivonne Gluth, Jennifer C. Lück & Olga I. Fonseca da Cruz Lopes. (2023) Real world data of a German Parkinson’s disease population: effectiveness and safety of safinamide in routine clinical practice. Current Medical Research and Opinion 0:0, pages 1-8.
Read now
Read now
Andrew Lees, Eduardo Tolosa, Fabrizio Stocchi, Joaquim J. Ferreira, Olivier Rascol, Angelo Antonini & Werner Poewe. (2023) Optimizing levodopa therapy, when and how? Perspectives on the importance of delivery and the potential for an early combination approach. Expert Review of Neurotherapeutics 23:1, pages 15-24.
Read now
Read now
Daniela Secci, Simone Carradori, Anél Petzer, Paolo Guglielmi, Melissa D’Ascenzio, Paola Chimenti, Donatella Bagetta, Stefano Alcaro, Gokhan Zengin, Jacobus P. Petzer & Francesco Ortuso. (2019) 4-(3-Nitrophenyl)thiazol-2-ylhydrazone derivatives as antioxidants and selective hMAO-B inhibitors: synthesis, biological activity and computational analysis. Journal of Enzyme Inhibition and Medicinal Chemistry 34:1, pages 597-612.
Read now
Read now
Thomas Müller. (2016) Emerging approaches in Parkinson’s disease – adjunctive role of safinamide. Therapeutics and Clinical Risk Management 12, pages 1151-1160.
Read now
Read now
Bandar E. Al-Dhubiab, Anroop B. Nair, Rachna Kumria, Mahesh Attimarad & Sree Harsha. (2016) Development and evaluation of buccal films impregnated with selegiline-loaded nanospheres. Drug Delivery 23:7, pages 2154-2162.
Read now
Read now
Santiago Perez-Lloret & Olivier Rascol. (2016) The safety and efficacy of safinamide mesylate for the treatment of Parkinson’s disease. Expert Review of Neurotherapeutics 16:3, pages 245-258.
Read now
Read now
Stefano de Biase, Giovanni Merlino, Simone Lorenzut, Mariarosaria Valente & Gian Luigi Gigli. (2014) ADMET considerations when prescribing novel therapeutics to treat restless legs syndrome. Expert Opinion on Drug Metabolism & Toxicology 10:10, pages 1365-1380.
Read now
Read now
Livia Dézsi & László Vécsei. (2014)
Safinamide for the treatment of Parkinson's disease. Expert Opinion on Investigational Drugs 23:5, pages 729-742.
Read now
Read now
Fabio Blandini & Marie-Therese Armentero. (2014) Dopamine receptor agonists for Parkinson's disease. Expert Opinion on Investigational Drugs 23:3, pages 387-410.
Read now
Read now
Thomas Müller. (2013) Current status of safinamide for the drug portfolio of Parkinson’s disease therapy. Expert Review of Neurotherapeutics 13:9, pages 969-977.
Read now
Read now
Anthony HV Schapira. (2010) Safinamide in the treatment of Parkinson's disease. Expert Opinion on Pharmacotherapy 11:13, pages 2261-2268.
Read now
Read now
Articles from other publishers (52)
Carlo Cattaneo & Jaime Kulisevsky. (2023) The Effects of Safinamide in Chinese and Non-Chinese Patients with Parkinson’s Disease. Advances in Therapy.
Crossref
Crossref
M. T. Pellecchia, M. Picillo, M. C. Russillo, V. Andreozzi, C. Oliveros & C. Cattaneo. (2023) The effects of safinamide according to gender in Chinese parkinsonian patients. Scientific Reports 13:1.
Crossref
Crossref
Laila Aboulatta, Lara Haidar, Ahmed Abou-Setta, Nicole Askin, Rasheda Rabbani, Alekhya Lavu, Payam Peymani, Ryan Zarychanski & Sherif Eltonsy. (2023) Efficacy and Safety of MAO-B Inhibitors Safinamide and Zonisamide in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. CNS Drugs 37:11, pages 941-956.
Crossref
Crossref
Sun Jing, Yaozong Yuan, Chiara Leuratti, Valentina Vaja & Carlo Cattaneo. (2023) Pharmacokinetic and Safety Study of Single and Multiple Oral Doses of Safinamide in Healthy Chinese Volunteers. Clinical Pharmacology in Drug Development 12:11, pages 1104-1113.
Crossref
Crossref
Zhiren Wang, Karina Marie Gonzalez, Leyla Estrella Cordova & Jianqin Lu. (2023) Nanotechnology‐empowered therapeutics targeting neurodegenerative diseases. WIREs Nanomedicine and Nanobiotechnology 15:5.
Crossref
Crossref
Bruno Bergmans, Philip Bourgeois, Patrick Cras, Sophie Dethy, Nina De Klippel, Gianni Franco, Gaëtan Garraux, Karine Geens, Philippe Jacquerye, Anne Jeanjean, Frédéric Supiot, Chris Van der Linden & Claude Krygier. (2022) Effectiveness and safety of safinamide in routine clinical practice in a Belgian Parkinson’s disease population: an open-label, levodopa add-on study. Acta Neurologica Belgica 123:3, pages 939-947.
Crossref
Crossref
Thian-Sze Wong, Guangzhi Li, Shiliang Li, Wei Gao, Geng Chen, Shiyi Gan, Manzhan Zhang, Honglin Li, Song Wu & Yang Du. (2023) G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders. Signal Transduction and Targeted Therapy 8:1.
Crossref
Crossref
Domiziana Rinaldi, Marika Alborghetti, Edoardo Bianchini, Michela Sforza, Silvia Galli & Francesco E. Pontieri. (2023) Monoamine-oxidase Type B Inhibitors and Cognitive Functions in Parkinson’s
Disease: Beyond the Primary Mechanism of Action. Current Neuropharmacology 21:5, pages 1214-1223.
Crossref
Crossref
Zhi Xin Chew, Chooi Ling Lim, Khuen Yen Ng, Soi Moi Chye, Anna Pick Kiong Ling & Rhun Yian Koh. (2023) The Role of Monoamine Oxidase B Inhibitors in the Treatment of Parkinson’s
Disease - An Update. CNS & Neurological Disorders - Drug Targets 22:3, pages 329-352.
Crossref
Crossref
Maria Claudia Russillo, Valentina Andreozzi, Roberto Erro, Marina Picillo, Marianna Amboni, Sofia Cuoco, Paolo Barone & Maria Teresa Pellecchia. (2022) Sex Differences in Parkinson’s Disease: From Bench to Bedside. Brain Sciences 12:7, pages 917.
Crossref
Crossref
Wolfgang H. Jost. (2022) A critical appraisal of MAO-B inhibitors in the treatment of Parkinson’s disease. Journal of Neural Transmission 129:5-6, pages 723-736.
Crossref
Crossref
Jörg Hohmann. (2022) Die Grenze zwischen Behandler und Kostenträger darf nicht verschwimmen. NeuroTransmitter 33:1-2, pages 28-31.
Crossref
Crossref
Zhizheng Wang, Chao Yi, Kangzhi Chen, Tao Wang, Kang Deng, Chuanfei Jin & Gefei Hao. (2022) Enhancing monoamine oxidase B inhibitory activity via chiral fluorination: Structure-activity relationship, biological evaluation, and molecular docking study. European Journal of Medicinal Chemistry 228, pages 114025.
Crossref
Crossref
Himika Wasan, Devendra Singh & Reeta KH. (2021) Safinamide in neurological disorders and beyond: Evidence from preclinical and clinical studies. Brain Research Bulletin 168, pages 165-177.
Crossref
Crossref
Jagadeesh Babu Nanubolu. (2020)
Conformational Polymorphism in Safinamide Acid Hydrochloride (
Z
′ = 3 and
Z
′ = 1) and Observation of a Temperature-Dependent Reversible Single-Crystal to Single-Crystal Phase Transformation of High-
Z
′ form (
Z
′ = 3 ↔
Z
′ = 2 via an Intermediate
Z
′ = 4)
. Crystal Growth & Design 21:1, pages 133-148.
Crossref
Crossref
Della G.T. Parambi. (2020) Treatment of Parkinson’s Disease by MAO-B Inhibitors, New Therapies and Future Challenges - A Mini-Review. Combinatorial Chemistry & High Throughput Screening 23:9, pages 847-861.
Crossref
Crossref
Kyung-Tai Kim, Da-Hee Kim, Bo-Kyung Kim, Ji-Seok Han, Han Young Eom, Mi-Jin Yang, Seung-Hyuk Shin, Doo-Wan Cho, Bo Ko Jang, Ki Duk Park, Young-Su Yang & Su-Cheol Han. (2020) Four-week repeated dose oral toxicity study of KDS2010, a novel selective monoamine oxidase B inhibitor, in Sprague Dawley rats. Regulatory Toxicology and Pharmacology 117, pages 104733.
Crossref
Crossref
Lei Gao, Qian Liu & Xian-Rui Zhang. (2020) Enhancing the Solubility and Dissolution Performance of Safinamide Using Salts. Crystals 10:11, pages 989.
Crossref
Crossref
Maria Rita Lo Monaco, Martina Petracca, Davide Liborio Vetrano, Enrico Di Stasio, Domenico Fusco, Diego Ricciardi, Alice Laudisio, Giuseppe Zuccalà, Graziano Onder & Anna Rita Bentivoglio. (2020) Safinamide as an adjunct therapy in older patients with Parkinson’s disease: a retrospective study. Aging Clinical and Experimental Research 32:7, pages 1369-1373.
Crossref
Crossref
Miriam Sciaccaluga, Petra Mazzocchetti, Guendalina Bastioli, Veronica Ghiglieri, Antonella Cardinale, Paolo Mosci, Carla Caccia, Charlotte Keywood, Elsa Melloni, Gloria Padoani, Silvia Vailati, Barbara Picconi, Paolo Calabresi & Alessandro Tozzi. (2020) Effects of safinamide on the glutamatergic striatal network in experimental Parkinson’s disease. Neuropharmacology 170, pages 108024.
Crossref
Crossref
Bárbara Mendes-Pinheiro, Ana Marote, Cláudia R. Marques, Fábio G. Teixeira, Jorge Cibrão Ribeiro & António J. Salgado. 2020. Mesenchymal Stem Cells in Human Health and Diseases. Mesenchymal Stem Cells in Human Health and Diseases
79
114
.
Maria Laura Ester Bianchi, Giulio Riboldazzi, Marco Mauri & Maurizio Versino. (2018) Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson’s disease. Neurological Sciences 40:2, pages 275-279.
Crossref
Crossref
Kewal K. JainKewal K. Jain. 2019. The Handbook of Neuroprotection. The Handbook of Neuroprotection
403
463
.
Margherita Fabbri, Mario M. Rosa & Joaquim J. Ferreira. (2018) Adjunctive Therapies in Parkinson’s Disease: How to Choose the Best Treatment Strategy Approach. Drugs & Aging 35:12, pages 1041-1054.
Crossref
Crossref
Francesca Mancini, Alessio Di Fonzo, Giulia Lazzeri, Linda Borellini, Vincenzo Silani, Marco Lacerenza & Cristoforo Comi. (2018) Real life evaluation of safinamide effectiveness in Parkinson’s disease. Neurological Sciences 39:4, pages 733-739.
Crossref
Crossref
Fábio G. Teixeira, Miguel F. Gago, Paulo Marques, Pedro Silva Moreira, Ricardo Magalhães, Nuno Sousa & António J. Salgado. (2018) Safinamide: a new hope for Parkinson’s disease?. Drug Discovery Today 23:3, pages 736-744.
Crossref
Crossref
Michele Morari, Alberto Brugnoli, Clarissa Anna Pisanò, Salvatore Novello, Carla Caccia, Elsa Melloni, Gloria Padoani, Silvia Vailati & Marco Sardina. (2018) Safinamide Differentially Modulates In Vivo Glutamate and GABA Release in the Rat Hippocampus and Basal Ganglia. Journal of Pharmacology and Experimental Therapeutics 364:2, pages 198-206.
Crossref
Crossref
Seul Ki Yeon, Ji Won Choi, Jong-Hyun Park, Ye Rim Lee, Hyeon Jeong Kim, Su Jeong Shin, Bo Ko Jang, Siwon Kim, Yong-Sun Bahn, Gyoonhee Han, Yong Sup Lee, Ae Nim Pae & Ki Duk Park. (2018) Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson’s disease therapy. Bioorganic & Medicinal Chemistry 26:1, pages 232-244.
Crossref
Crossref
Ana O. Pires, F.G. Teixeira, B. Mendes-Pinheiro, Sofia C. Serra, Nuno Sousa & António J. Salgado. (2017) Old and new challenges in Parkinson's disease therapeutics. Progress in Neurobiology 156, pages 69-89.
Crossref
Crossref
Mehdi Rimaz, Farkhondeh Aali, Behzad Khalili & Rolf H. Prager. (2017) A Green and Convenient Route for the Regioselective Synthesis of New Substituted 3-Aryl-5H-indeno[1,2-c]pyridazines as Potential Monoamine Oxidase Type A Inhibitors. Australian Journal of Chemistry 70:6, pages 660.
Crossref
Crossref
Luca Loprete, Chiara Leuratti, Carlo Cattaneo, Mita M. Thapar, Colm Farrell & Marco Sardina. (2016) Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson's disease. Pharmacology Research & Perspectives 4:5.
Crossref
Crossref
Samantha J. Podurgiel, Samantha E. Yohn, Kristina Dortche, Merce Correa & John D. Salamone. (2016) The MAO-B inhibitor deprenyl reduces the oral tremor and the dopamine depletion induced by the VMAT-2 inhibitor tetrabenazine. Behavioural Brain Research 298, pages 188-191.
Crossref
Crossref
Zhi-Min Wang, Xue-Mei Li, Wei Xu, Fan Li, Jin Wang, Ling-Yi Kong & Xiao-Bing Wang. (2015) Acetophenone derivatives: novel and potent small molecule inhibitors of monoamine oxidase B. MedChemComm 6:12, pages 2146-2157.
Crossref
Crossref
Margherita Fabbri, Mario M Rosa, Daisy Abreu & Joaquim J Ferreira. (2015) Clinical pharmacology review of safinamide for the treatment of Parkinson’s disease. Neurodegenerative Disease Management 5:6, pages 481-496.
Crossref
Crossref
Carlo Cattaneo, R. La Ferla, Erminio Bonizzoni & Marco Sardina. (2015) Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson’s Disease: A Post-Hoc Analysis. Journal of Parkinson's Disease 5:3, pages 475-481.
Crossref
Crossref
Jin Yong Chung, Ji Won Lee, Choon Ho Ryu, Hye Kyung Min, Yeo Jin Yoon, Mi Jung Lim & Cheol Hyoung Park. (2015) 1-[2-(4-Benzyloxyphenoxy)Ethyl]Imidazole inhibits monoamine oxidase B and protects against neuronal loss and behavioral impairment in rodent models of Parkinson's disease. Journal of Neuroscience Research 93:8, pages 1267-1278.
Crossref
Crossref
Ashish Kumar Kakkar & Neha Dahiya. (2015) Management of Parkinson׳s disease: Current and future pharmacotherapy. European Journal of Pharmacology 750, pages 74-81.
Crossref
Crossref
Nikolay T. Tzvetkov, Sonja Hinz, Petra Küppers, Marcus Gastreich & Christa E. Müller. (2014) Indazole- and Indole-5-carboxamides: Selective and Reversible Monoamine Oxidase B Inhibitors with Subnanomolar Potency. Journal of Medicinal Chemistry 57:15, pages 6679-6703.
Crossref
Crossref
Amit Shard, Rajesh Kumar, Saima SaimaNidhi Sharma & Arun K. Sinha. (2014) Amino acid and water-driven tunable green protocol to access S–S/C–S bonds via aerobic oxidative coupling and hydrothiolation. RSC Adv. 4:63, pages 33399-33407.
Crossref
Crossref
Laurent Grégoire, Vincent A. Jourdain, Matthew Townsend, Arthur Roach & Thérèse Di Paolo. (2013) Safinamide reduces dyskinesias and prolongs l-DOPA antiparkinsonian effect in parkinsonian monkeys. Parkinsonism & Related Disorders 19:5, pages 508-514.
Crossref
Crossref
Damineh Morsali, David Bechtold, Woojin Lee, Summen Chauhdry, Upayan Palchaudhuri, Paula Hassoon, Daniel M. Snell, Katy Malpass, Thomas Piers, Jennifer Pocock, Arthur Roach & Kenneth J. Smith. (2013) Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis. Brain 136:4, pages 1067-1082.
Crossref
Crossref
Samantha Podurgiel, Lyndsey E. Collins-Praino, Samantha Yohn, Patrick A. Randall, Arthur Roach, Christophe Lobianco & John D. Salamone. (2013) Tremorolytic effects of safinamide in animal models of drug-induced parkinsonian tremor. Pharmacology Biochemistry and Behavior 105, pages 105-111.
Crossref
Crossref
Annick Seithel‐Keuth, Andreas Johne, Achim Freisleben, Katrin Kupas, Michael Lissy & Sonja Krösser. (2013) Absolute Bioavailability and Effect of Food on the Disposition of Safinamide Immediate Release Tablets in Healthy Adult Subjects. Clinical Pharmacology in Drug Development 2:1, pages 79-89.
Crossref
Crossref
Sonja Krösser, Anne Marquet, Dieter Gallemann, Peter Wolna, Nicolas Fauchoux, Robert Hermann & Andreas Johne. (2012) Effects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjects. Biopharmaceutics & Drug Disposition 33:9, pages 550-559.
Crossref
Crossref
Vivekkumar K. Redasani, Bhushan J. Mali & Sanjay J. Surana. (2012) Development and Validation of HPTLC Method for Estimation of Safinamide Mesylate in Bulk and in Tablet Dosage Form. ISRN Analytical Chemistry 2012, pages 1-4.
Crossref
Crossref
Fabrizio Stocchi, Rupam Borgohain, Marco Onofrj, Anthony H.V. Schapira, Mohit Bhatt, Valentina Lucini, Rodolfo Giuliani & Ravi Anand. (2012) A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients. Movement Disorders 27:1, pages 106-112.
Crossref
Crossref
Mahmoud M. Iravani & Peter Jenner. (2011) Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. Journal of Neural Transmission 118:12, pages 1661-1690.
Crossref
Crossref
Kai Zhang, Na Xue, Xiaowei Shi, Weina Liu, Jing Meng & Yumin Du. (2011) A validated chiral liquid chromatographic method for the enantiomeric separation of safinamide mesilate, a new anti-Parkinson drug. Journal of Pharmaceutical and Biomedical Analysis 55:1, pages 220-224.
Crossref
Crossref
Kewal K. JainKewal K. Jain. 2011. The Handbook of Neuroprotection. The Handbook of Neuroprotection
297
336
.
S. Tsouli & S. Konitsiotis. (2010) How should we treat a patient with early Parkinson’s disease?. International Journal of Clinical Practice 64:9, pages 1210-1219.
Crossref
Crossref
David J. Burn. (2010) The Treatment of Cognitive Impairment Associated with Parkinson's Disease. Brain Pathology 20:3, pages 672-678.
Crossref
Crossref
Leonardo Pisani, Giovanni Muncipinto, Teresa Fabiola Miscioscia, Orazio Nicolotti, Francesco Leonetti, Marco Catto, Carla Caccia, Patricia Salvati, Ramon Soto-Otero, Estefania Mendez-Alvarez, Celine Passeleu & Angelo Carotti. (2009)
Discovery of a Novel Class of Potent Coumarin Monoamine Oxidase B Inhibitors: Development and Biopharmacological Profiling of 7-[(3-Chlorobenzyl)oxy]-4-[(methylamino)methyl]-2
H
-chromen-2-one Methanesulfonate (NW-1772) as a Highly Potent, Selective, Reversible, and Orally Active Monoamine Oxidase B Inhibitor
. Journal of Medicinal Chemistry 52:21, pages 6685-6706.
Crossref
Crossref